As Marketplace health plan premiums rise and subsidies shift, employers are seeing more requests from employees (and their spouses) to drop Marketplace coverage and enroll in an employer-sponsored health plan mid-year. While this may feel straightforward, Marketplace rules and employer plan rules do not always work the same way.
Marketplace Rules vs. Employer Plan Rules
Marketplace coverage, as part of the individual insurance market, is designed to adjust for changes in cost and affordability. Employer-sponsored health plans, however, follow specific federal rules that limit mid-year enrollment to defined HIPAA special enrollment situations.
Loss of Eligibility vs. Voluntary Termination
For employer health plans, mid-year enrollment requires a loss of eligibility for other coverage — not simply a choice to end that coverage. Voluntarily terminating Marketplace coverage, even due to higher premiums or reduced subsidies, does not create a HIPAA special enrollment right if the individual remained eligible to continue that Marketplace coverage.
In these situations, enrollment in the employer’s health plan must wait until the employer’s next open enrollment period, unless a separate HIPAA special enrollment event applies.
What Does Qualify
Examples of situations that may create a mid-year HIPAA special enrollment right include:
- Loss of coverage due to job loss or a reduction in hours that ends eligibility
- Divorce or legal separation resulting in loss of coverage under a spouse’s plan
- A dependent aging off a parent’s plan at the plan’s limiting age
- Exhaustion of COBRA coverage
- A carrier exiting the market or discontinuing a specific product
- Moving out of a plan’s service area so coverage is no longer available
Timing Matters
Even when a mid-year special enrollment right does not apply, employees may leave Marketplace coverage and enroll in an employer-sponsored health plan during the employer’s annual open enrollment period. Coordinating effective dates is important to avoid gaps in coverage.
Why This Matters for Employers
Understanding these distinctions helps employers:
- Set clear expectations with employees
- Avoid enrollment errors and inconsistent practices
- Reduce the risk of claims issues or coverage disputes later in the year
If you have questions about mid-year enrollment requests or special enrollment rules, contact your INSURICA service team for guidance.
This is not intended to be exhaustive nor should any discussion or opinions be construed as legal advice. Readers should contact legal counsel or an insurance professional for appropriate advice.
About the Author
Share This Story
Related Blogs
Fiduciary Responsibilities for Employer Health Plans: What Employers Should Know Now
When employers think about fiduciary responsibility, retirement plans often come to mind first. But recent developments make it clear that fiduciary duties also matter—sometimes significantly—when it comes to employer-sponsored health and welfare plans.
The New Era of Mental Health Parity Enforcement in 2026
Federal agencies have made mental health parity enforcement a top priority in 2026, and employers sponsoring group health plans are feeling the impact. Regulators are no longer satisfied with high‑level assurances that plans comply with the Mental Health Parity and Addiction Equity Act (MHPAEA). Instead, they expect detailed, data‑driven documentation showing that mental health and substance‑use‑disorder benefits are truly comparable to medical and surgical benefits. This includes not only the written plan design but also how rules are applied in real‑world scenarios.
The 2026 Specialty Drug Surge: What Employers Need to Prepare For
Specialty drugs have been a major cost driver for years, but 2026 marks a significant shift in both scale and urgency. With GLP 1 medications expanding into new indications, gene therapies entering the market at record pace, and oncology drugs continuing to rise in both cost and utilization, specialty medications are projected to account for more than 60% of total pharmacy spending this year. That’s a dramatic change for employers, especially considering that specialty drugs represent fewer than 5% of total prescriptions.










